Clinical Nutrition Open Science最新文献

{"title":"A preliminary randomized controlled trial of a ginger-containing, clear, fat-free oral nutritional Supplement for chemotherapy-induced nausea and nutritional outcomes","authors":"Rie Tsutsumi ,&nbsp;Soshi Narasaki ,&nbsp;Yousuke T. Horikawa ,&nbsp;Yuna Izumi-Mishima ,&nbsp;Sonoko Yasui-Yamada ,&nbsp;Kazuhiro Nomura ,&nbsp;Hiroshi Sakaue ,&nbsp;Yasuo M. Tsutsumi","doi":"10.1016/j.nutos.2025.12.011","DOIUrl":"10.1016/j.nutos.2025.12.011","url":null,"abstract":"<div><h3>Purpose</h3><div>Chemotherapy-induced nausea and vomiting (CINV) is a serious side effect, affecting approximately 40% of cancer patients and often hindering their ability to continue treatment. In this study, we evaluated the efficacy of an oral nutrition supplement (ONS) designed to decrease patients experiencing CINV.</div></div><div><h3>Methods</h3><div>A total of 98 patients were assessed for eligibility, and 75 patients were prospectively and randomly assigned to one of three groups: the control group without ONS (Control; n = 25), a fat-free clear ONS including ginger extract group (Ginger ONS; n = 25), or the Conventional ONS group (Conv ONS; n = 25). Data collection included Numerical Rating Scale (NRS) for nausea, number of vomiting episodes, use of antiemetic drugs, blood biochemical tests, serum substance P levels, Quality of Life (QOL) Assessment, and dietary intake.</div></div><div><h3>Results</h3><div>NRS for nausea scores after the second cycle of chemotherapy were 7.8 ± 1.8 in the Control group, 3.5 ± 1.4 in the Ginger ONS group, and 5.7 ± 1.9 in the Conv ONS group. Substance P levels decreased significantly in the Ginger ONS group compared to the Conv ONS and Control groups. In addition, the Ginger ONS group showed a significant improvement in energy and protein intake. Body weight and lean body mass were also improved. Finally, QOL was significantly improved in the Ginger ONS group following the second cycle of chemotherapy (<em>P</em> &lt; 0.05).</div></div><div><h3>Conclusions</h3><div>Taken together, these data suggest that Ginger ONS is associated with improvements in nausea and energy/protein intake following chemotherapy. It is possible that comprehensive differences in nutritional composition—including the ginger extract, the amount and quality of protein, absence of fat, palatability, etc.—may have contributed to the observed outcomes.</div></div><div><h3>Trial Registry</h3><div><span><span>https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000060201</span><svg><path></path></svg></span>.</div></div>","PeriodicalId":36134,"journal":{"name":"Clinical Nutrition Open Science","volume":"66 ","pages":"Article 100617"},"PeriodicalIF":0.0,"publicationDate":"2026-01-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146070927","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effects of ubiquinol on metabolic profile in prediabetic patients: A randomized, double-blinded, placebo-controlled pilot study","authors":"Pasita Palakornkitti ,&nbsp;Romun Leaovitavat ,&nbsp;Paphitchaya Thetsana ,&nbsp;Patana Teng-umnuay","doi":"10.1016/j.nutos.2026.100627","DOIUrl":"10.1016/j.nutos.2026.100627","url":null,"abstract":"<div><h3>Background/objectives</h3><div>Prediabetes not only increase the risk of developing diabetes, but it is also associated with the development of cardiovascular disease, chronic kidney disease, neuropathy, and retinopathy. Oxidative stress is a well-known contributor to its pathogenesis. This study aimed to examine the potential benefit effect of ubiquinol supplementation, a lipophilic antioxidant, on metabolic profile in prediabetic patients.</div></div><div><h3>Methods</h3><div>This prospective, randomized, double-blind, placebo-controlled pilot study enrolled 20 adults with impaired fasting plasma glucose (FPG), who were randomly assigned to receive ubiquinol (100 mg per day) or placebo. Metabolic profile including FPG, hemoglobin A1C (HbA1C), fasting insulin, homeostasis model assessment of insulin resistance (HOMA-IR), total cholesterol, low-density lipoprotein (LDL), high-density lipoprotein (HDL), and triglyceride (TG) was assessed after 12-week treatment period. Between-group differences were analyzed according to the intention-to-treat principle, with effect sizes calculated to estimate the magnitude of observed effects.</div></div><div><h3>Results</h3><div>HOMA-IR was significantly lower in ubiquinol group compared to placebo group at week 12 (<em>P</em> = 0.028), with a moderate effect size (r =0.490). Median (range) HOMA-IR reduced from 2.23 (0.97) to 1.66 (0.39) for ubiquinol group while increased from 2.20 (0.90) to 2.35 (1.90) for placebo group. No significant difference in other outcome was reported. However, moderate-to-large effect sizes were observed for FPG, HbA1C, and fasting insulin.</div></div><div><h3>Conclusions</h3><div>Daily supplementation of 100-mg ubiquinol for 12 weeks improves insulin sensitivity for prediabetic patients with a favorable safety profile. The observed effect sizes support further investigation in larger, adequately powered trials to confirm the metabolic effects of ubiquinol.</div></div>","PeriodicalId":36134,"journal":{"name":"Clinical Nutrition Open Science","volume":"66 ","pages":"Article 100627"},"PeriodicalIF":0.0,"publicationDate":"2026-01-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146070926","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Changes in taste and smell function during adjuvant chemotherapy in patients with colon cancer: A prospective cohort study","authors":"K. Beukers ,&nbsp;A.J. van de Wouw ,&nbsp;R.C. Havermans ,&nbsp;M.L.G. Janssen-Heijnen","doi":"10.1016/j.nutos.2026.100626","DOIUrl":"10.1016/j.nutos.2026.100626","url":null,"abstract":"<div><h3>Background &amp; aims</h3><div>Adjuvant chemotherapy for high-risk stage II or stage III colon cancer improves survival, but frequently induces side effects, including changes in taste (hypogeusia) and smell (hyposmia) function. These alterations in taste and smell function may reduce appetite and nutritional intake, increasing the risk of malnutrition and compromising treatment tolerance and quality of life. Objective data on these changes during chemotherapy are limited. The aim of this study was to investigate changes in taste and smell function during adjuvant chemotherapy in patients with colon cancer.</div></div><div><h3>Methods</h3><div>In this relatively small prospective cohort study, eleven patients with high-risk stage II or III colon cancer receiving capecitabine or CAPOX were included. Taste and smell function were assessed using Taste Strips and Sniffin’ Sticks before, during, and after chemotherapy. Paired-samples t-tests compared taste and smell function at each time point to baseline.</div></div><div><h3>Results</h3><div>Significant declines in taste (T1; mean difference = -1.33, p = 0.022) and smell (T1; mean difference = -5.11, p = 0.017) were observed after the first chemotherapy cycle. Baseline hypogeusia and hyposmia were present in 33% and 44% of patients, respectively. During treatment, hypogeusia ranged from 33–44% and hyposmia from 44–78%, with marked inter- and intra-individual variability. While most patients maintained normogeusia, hyposmia was more common at multiple time points.</div></div><div><h3>Conclusion</h3><div>Adjuvant chemotherapy is associated with clinically relevant, but heterogeneous changes in taste and smell, particularly during the initial phase of chemotherapy. These alterations may impair nutritional intake, highlighting the need for early, individualized dietary interventions. Combining objective and patient-reported assessments may optimize supportive care, enhancing treatment tolerance and quality of life. Despite the small sample size, which substantially limits generalizability, the in-depth analysis highlights significant variability in taste and smell function both between patients and across chemotherapy cycles, highlighting that chemosensory changes are neither uniform nor static.</div></div>","PeriodicalId":36134,"journal":{"name":"Clinical Nutrition Open Science","volume":"65 ","pages":"Article 100626"},"PeriodicalIF":0.0,"publicationDate":"2026-01-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146038704","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A multicenter study evaluating the gastrointestinal tolerance and acceptability of a novel high-energy, high-protein, plant-based enteral tube feed for adults","authors":"James Evans ,&nbsp;Antonino Salvia ,&nbsp;Rosa Maria Burgos ,&nbsp;Fernanda Mucarzel ,&nbsp;Sharan Saduera","doi":"10.1016/j.nutos.2025.100624","DOIUrl":"10.1016/j.nutos.2025.100624","url":null,"abstract":"<div><h3>Background &amp; Aims</h3><div>In 2023, 2.6 million Europeans were estimated to be vegan, approximately 3 % of the European population. Few plant-based products exist for patients who need tube feeding. Furthermore, the tube-fed population often have gastrointestinal intolerance to milk-based proteins due to underlying pathology. A plant-based feed may be better tolerated. This study aimed to evaluate acceptability, compliance and gastrointestinal tolerance of a novel high-energy, high-protein, plant-based enteral tube feed.</div></div><div><h3>Methods</h3><div>A single-arm, prospective study in three centers was conducted. Adults ≥16 years, established on a tube feed for disease-related malnutrition which provided ≥50 % of energy requirements were included. Patients were swapped from their usual feed to the study product Compleat® plant protein 1.6 (a plant-based, high-energy, high-protein tube feed) for seven days. Acceptability (patient satisfaction), compliance (volume of feed taken versus prescribed) and gastrointestinal tolerance (diarrhea, constipation, vomiting, nausea) were assessed by self-reported questionnaire. This included multiple-choice questions, Likert scales and free text comments.</div></div><div><h3>Results</h3><div>Twenty-one patients were recruited, of which five withdrew, two due to worsening gastrointestinal symptoms with the study product. Sixteen patients completed data collection, mean age 53.3 years, 44 % female, 56 % had cancer, 75 % had a gastrostomy. Mean daily volume of Compleat® plant protein 1.6 consumed versus prescribed was 992 mL v 1058 mL (94 % compliance). Mean calorie and protein intake was 1555 kcals and 82.6 g respectively and 69 % tolerated the study feed with no change in gastrointestinal symptoms compared to baseline, whilst 25 % reported significant improvements in their gastrointestinal symptoms. Forty four percent were satisfied with the new feed, 38 % were neither satisfied nor dissatisfied.</div></div><div><h3>Conclusions</h3><div>Compleat® plant protein 1.6 was very acceptable to patients and associated with high levels of compliance and good gastrointestinal tolerance. For patients who follow a plant-based diet Compleat® plant protein 1.6 offers an innovative enteral tube feed that does not contain added milk or soya ingredients. Clinicians could consider this feed when patients have gastrointestinal intolerance to a milk-based feed.</div></div>","PeriodicalId":36134,"journal":{"name":"Clinical Nutrition Open Science","volume":"65 ","pages":"Article 100624"},"PeriodicalIF":0.0,"publicationDate":"2026-01-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145979062","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A novel egg white-based solid oral nutritional supplement improves serum albumin and protein intake in patients on peritoneal dialysis: A prospective interventional study","authors":"Yupa Chanwikrai ,&nbsp;Kamonwan Jongsomchai ,&nbsp;Guttiga Halue ,&nbsp;Donkum Kaewboonsert ,&nbsp;Sawitree Suwannasang ,&nbsp;Wittawas Sajjapong","doi":"10.1016/j.nutos.2025.100621","DOIUrl":"10.1016/j.nutos.2025.100621","url":null,"abstract":"<div><h3>Background &amp; aims</h3><div>Protein-energy wasting (PEW) is a major predictor of adverse outcomes in patients undergoing continuous ambulatory peritoneal dialysis (CAPD). Achieving the recommended dietary protein intake remains a significant clinical challenge. This study aimed to evaluate the safety and efficacy of “Egg Bite,” a novel, palatable, solid oral nutritional supplement (ONS) derived from egg white, in improving the nutritional status of CAPD patients.</div></div><div><h3>Methods</h3><div>In this prospective, single-arm interventional trial, 35 CAPD patients with serum albumin ≤ 4.0 g/dL consumed a daily supplement of “Egg Bite” (105 g/day, providing 25.7 g protein and 392 kcal) for 21 consecutive days. The primary outcome was the change in serum albumin. Secondary outcomes included changes in overall dietary intake, anthropometric measures, and key biochemical markers (renal, metabolic, and inflammatory). Assessments were performed at baseline, day 14, and day 21.</div></div><div><h3>Results</h3><div>Thirty-five of 42 enrolled patients (83%) completed the study. Daily supplementation resulted in a significant increase in mean serum albumin from 3.38 ± 0.42 g/dL at baseline to 3.48 ± 0.43 g/dL at day 21 (<em>P</em> = 0.001). Total protein intake rose significantly from 0.9 ± 0.2 g/kg/day to 1.4 ± 0.4 g/kg/day (<em>P</em> &lt; 0.001), successfully meeting guideline recommendations. Energy intake also increased significantly (<em>P</em> &lt; 0.001). No significant changes were observed in body weight or BMI. The supplement was well-tolerated, with non-significant increases in serum potassium and stable hemoglobin levels. Minor but statistically significant increases in BUN and creatinine were noted, consistent with increased protein metabolism. In patients with baseline hypoalbuminemia (n=19), hs-CRP showed a non-significant downward trend from 10.44 to 8.10 mg/dL.</div></div><div><h3>Conclusions</h3><div>Daily supplementation with “Egg Bite,” a novel egg white-based solid ONS, is a safe, well-tolerated, and effective intervention for improving protein-energy status in CAPD patients. It significantly elevates serum albumin and dietary protein intake to meet clinical targets without inducing adverse metabolic effects. “Egg Bite” represents a promising tool for managing PEW, though longer-term studies are needed to evaluate its impact on body composition and clinical outcomes.</div></div>","PeriodicalId":36134,"journal":{"name":"Clinical Nutrition Open Science","volume":"65 ","pages":"Article 100621"},"PeriodicalIF":0.0,"publicationDate":"2026-01-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145979063","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Linguistic and content validation of the patient-generated subjective global assessment (PG-SGA) in Indonesian for use by cancer patients and healthcare professionals","authors":"Annela Manurung ,&nbsp;Marcellus Simadibrata ,&nbsp;Andri Sanityoso S ,&nbsp;Ikhwan Rinaldi ,&nbsp;Faith D. Ottery","doi":"10.1016/j.nutos.2025.12.013","DOIUrl":"10.1016/j.nutos.2025.12.013","url":null,"abstract":"<div><h3>Background</h3><div>Assessment of malnutrition is important in cancer patients, especially in gastrointestinal cancer in Indonesia. The Scored Patient-Generated Subjective Global Assessment (PG-SGA), an instrument that allows interdisciplinary assessment of malnutrition and its risk factors, has yet to be available in the Indonesian version.</div></div><div><h3>Object</h3><div>To produce a valid and reliable PG-SGA questionnaire in Indonesian while maintaining the English version’s form, purpose, and meaning.</div></div><div><h3>Methods</h3><div>The PG-SGA questionnaire was translated, culturally and linguistically adapted, following the International Society for Pharmacoeconomics (ISPOR) principles. Each question item in the questionnaire will be assessed based on content validity, comprehensibility, and difficulty, operationalized by calculating item and scale indices. A scaled score of 0.80–0.90 is considered acceptable, while a score of more than 0.90 is considered excellent.</div></div><div><h3>Results</h3><div>The content validity of the entire PG-SGA questionnaire obtained an S-CVI of 0.92. The content validity score of the PG-SGA questionnaire on professional participants was S-CVI 0.91. The comprehensibility score of professional and general public participants was S–CI 0.89. The score for the difficulty of question items on the PG-SGA questionnaire with professional and general public participants obtained the results of S-DI 0.86 and 0.88.</div></div><div><h3>Conclusion</h3><div>The translation and cultural adaptation of the PG-SGA questionnaire according to the ISPOR principles of successfully maintaining the format, purpose, and meaning of the Indonesian version of the PG-SGA questionnaire. The PG-SGA questionnaire’s Indonesian version is now comprehensible and relevant for patients, the general public, and professionals. However, there are components of the professional questions that are considered difficult, so additional descriptions or brief explanations and training are needed, especially for physical examinations.</div></div>","PeriodicalId":36134,"journal":{"name":"Clinical Nutrition Open Science","volume":"65 ","pages":"Article 100619"},"PeriodicalIF":0.0,"publicationDate":"2025-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145940055","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The impact on ICU patients of new enteral nutrition formula designed to maintain autophagy that is low in carbohydrates and leucine and high in lipids","authors":"Shuhei Maruyama ,&nbsp;Daiki Wada ,&nbsp;Shuji Kanayama ,&nbsp;Hiromu Iwamura ,&nbsp;Junya Shimazaki ,&nbsp;Tomoyuki Yoshihara ,&nbsp;Fukuki Saito ,&nbsp;Kazuhisa Yoshiya ,&nbsp;Tomohiro Kagawa ,&nbsp;Ryosuke Akiyama ,&nbsp;Ippei Yamaoka ,&nbsp;Yasushi Nakamori ,&nbsp;Yasuyuki Kuwagata","doi":"10.1016/j.nutos.2025.100623","DOIUrl":"10.1016/j.nutos.2025.100623","url":null,"abstract":"&lt;div&gt;&lt;h3&gt;Background &amp; aims&lt;/h3&gt;&lt;div&gt;Given that the ESPEN 2019 guidelines state that “severe hypophosphatemia may lead to death after the initiation of feeding in patients admitted to intensive care unit (ICU),” we have been developing enteral nutrition (EN) formulas designed to reduce the risk of hypophosphatemia. Preliminary research indicates that high glucose concentrations and leucine-rich peptides are associated with hypophosphatemia across EN formulas with varying nutrient compositions. Additionally, recent randomized controlled trials have shown that high macronutrient doses, irrespective of the delivery route, may be harmful during the acute phase of critical illness, possibly due to the suppression of autophagy and ketogenesis, overfeeding-related hyperglycemia, and increased insulin requirements. EN formulas with lower glucose and leucine contents and higher lipid concentrations may activate autophagy and ketogenesis by inhibiting the mammalian target of rapamycin (mTOR) pathway. This study aimed to evaluate the clinical effect of a newly developed EN formula in critically ill patients.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Methods&lt;/h3&gt;&lt;div&gt;A newly developed EN formula was launched in September 2023. The composition of the new EN product is characterised by being low in carbohydrates, high in protein from peptides with low leucine content, and high in lipids. This single-center, retrospective cohort study was conducted in Japan to compare clinical outcomes between the new EN formula and the standard formula. Eligible patients were those admitted to the ICU for at least 10 days and requiring invasive mechanical ventilation for at least 3 days. Patients were categorized into the new EN group or standard EN group based on the enteral formula they received. The primary outcome was in-hospital mortality. Secondary outcomes included insulin doses and electrolyte levels (potassium, phosphate, and magnesium), bowel movement frequency, and the incidence of bowel ischemia. The baseline characteristics were adjusted using propensity score matching (PSM) and inverse probability of treatment weighting (IPTW), followed by multivariate logistic regression analysis.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Results&lt;/h3&gt;&lt;div&gt;Among the 689 eligible patients, 262 were assigned to the new EN group and 427 to the standard EN group. After PSM, 230 patients were included in each group. In IPTW analysis, 682 patients with complete data were included in the weighted population. The doses of insulin and electrolytes (potassium, phosphate, and magnesium) were consistently lower in the new EN group in both PSM and IPTW analyses. The in-hospital mortality was significantly lower in the new EN group than in the standard EN group (25 [10.9%] vs. 48 [20.9%], &lt;em&gt;P&lt;/em&gt; = 0.006 after PSM; &lt;em&gt;P&lt;/em&gt; = 0.002 after IPTW). Logistic regression analysis demonstrated that the new EN formulation was significantly associated with reduced in-hospital mortality both after PSM (OR: 0.46, 95% CI: 0.25–0.80, &lt;em&gt;P&lt;/e","PeriodicalId":36134,"journal":{"name":"Clinical Nutrition Open Science","volume":"65 ","pages":"Article 100623"},"PeriodicalIF":0.0,"publicationDate":"2025-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145940056","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-world implementation of a standardized ICU protocol for daytime-restricted enteral nutrition in critically ill adults: A retrospective quality improvement study","authors":"Kelsey Russell-Murray ,&nbsp;Hassan S. Dashti","doi":"10.1016/j.nutos.2025.100622","DOIUrl":"10.1016/j.nutos.2025.100622","url":null,"abstract":"<div><h3>Background</h3><div>Enteral nutrition (EN) delivery is often interrupted in the intensive care unit (ICU), and while continuous 24-hour feeding is standard practice, emerging evidence from circadian biology and pilot trials suggests that daytime-restricted EN may enhance nutritional adequacy and patient outcomes by aligning feeding with biological rhythms.</div></div><div><h3>Methods</h3><div>This quality improvement study describes a novel, standardized daytime-restricted EN protocol in a community hospital ICU and retrospectively evaluate its real-world implementation. The protocol involved a stepwise transition in EN delivery, beginning with continuous trophic feeding (acute/initial phase), followed by daytime-restricted 12-hour cyclic feeding (anabolic recovery phase), and advancing to intermittent daytime-restricted feeding (chronic recovery phase). A convenience sample of 22 adult ICU patients (12 received continuous 24-hour EN; 10 with the daytime-restricted EN protocol) was analyzed. Clinical data were extracted from electronic medical records, including EN infusion rates, duration, and interruptions.</div></div><div><h3>Results</h3><div>Patients in the daytime-restricted group received EN at higher infusion rates (median 87.5 vs. 40.0 mL/hr), over fewer hours per day (11.0 vs. 14.5 hours), experienced fewer interruptions (1.0 vs. 9.5 hours/day), and received a greater percentage of their prescribed nutritional volume (90.0% vs. 57.5%) compared to the continuous group (all <em>P</em> value &lt; 0.05). Vomiting was more frequently reported in the daytime-restricted group, while constipation was more common in the continuous group, though these differences were not statistically significant.</div></div><div><h3>Conclusion</h3><div>This preliminary evaluation supports the feasibility of implementing a daytime-restricted EN protocol in an adult ICU and suggests potential advantages in delivery consistency and nutritional adequacy. To support broader implementation, larger prospective studies across broader ICU populations are necessary.</div></div>","PeriodicalId":36134,"journal":{"name":"Clinical Nutrition Open Science","volume":"65 ","pages":"Article 100622"},"PeriodicalIF":0.0,"publicationDate":"2025-12-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145940053","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cachexia, sarcopenia, malnutrition and their impact on survival, treatment toxicities, and quality of life in locally advanced cervical cancer patients undergoing concomitant chemoradiotherapy: A scoping review","authors":"Canio Martinelli ,&nbsp;Alfredo Ercoli ,&nbsp;Luigi Alfano ,&nbsp;Francesca Pentimalli ,&nbsp;Giulio Mazzarotti ,&nbsp;Giacomo Ferrantelli ,&nbsp;Antonino De Lorenzo ,&nbsp;Teresa Esposito ,&nbsp;Antonio Giordano ,&nbsp;Salvatore Cortellino","doi":"10.1016/j.nutos.2025.100620","DOIUrl":"10.1016/j.nutos.2025.100620","url":null,"abstract":"<div><h3>Background</h3><div>Concurrent chemoradiotherapy for locally advanced cervical cancer (LACC) must be completed within 56 days, with each added day increasing recurrence risk by 1%. Sarcopenia, malnutrition, and cachexia affect 20–60% of patients, yet guidelines do not recommend routine screening, and their independent associations with outcomes remain unmapped.</div></div><div><h3>Methods</h3><div>We searched MEDLINE, Scopus, Web of Science, and Cochrane (1995–2025) for studies reporting cachexia, malnutrition, or sarcopenia with survival, toxicity, treatment completion, or quality of life in LACC patients receiving chemoradiotherapy. Two reviewers screened records, extracted data, and assessed bias using QUIPS.</div></div><div><h3>Results</h3><div>Twenty-three studies (4,352 women; cohorts 41–391) used heterogeneous definitions. Malnutrition was assessed in 17 studies, sarcopenia in 15, and cachexia in 2. Malnutrition showed 1.5- to 3.7-fold higher mortality. Chemotherapy-defined sarcopenia predicted survival in 5 of 11 assessments (HR 1.75–3.60); sarcopenic obesity carried HR 2.65. On-treatment body-composition loss showed strongest effects: ≥7–10% skeletal-muscle decline (HR 6.02) and ≥15% intermuscular fat loss (HR 8.52) predicted higher mortality. Grade ≥3 toxicity and treatment interruption were 1.2- to 2.5-fold more frequent in malnourished or sarcopenic women, increasing to 3–5-fold with multiple unfavorable body-composition features. Quality-of-life scores declined 11% during treatment. Seventeen studies had high bias risk from attrition and inadequate confounder control.</div></div><div><h3>Conclusions</h3><div>Malnutrition, sarcopenia, and cachexia correlate with poor survival and treatment tolerance in LACC chemoradiotherapy; on-treatment muscle loss shows strongest prognostic value. Screening at baseline and muscle quantification on chemotherapy can identify high-risk patients. Consensus definitions, prospective validation, and multimodal prehabilitation trials are needed before implementation.</div></div>","PeriodicalId":36134,"journal":{"name":"Clinical Nutrition Open Science","volume":"65 ","pages":"Article 100620"},"PeriodicalIF":0.0,"publicationDate":"2025-12-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145940054","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Corrigendum to “Effectiveness of omega-3 supplementation in reducing the degree of steatotic liver disease associated with metabolic dysfunction in adults” [Clinical Nutrition Open Science 64 (2025) 255–265]","authors":"María Dolores Mondéjar Barrios ,&nbsp;Karem Justhin Rodas Trujillo ,&nbsp;Juana Olga Espíritu Aguirre ,&nbsp;Matilde Anais Matos Inga ,&nbsp;Sandra Lisseth Mori Díaz ,&nbsp;Luis Alberto Cabanillas Chirinos","doi":"10.1016/j.nutos.2025.11.011","DOIUrl":"10.1016/j.nutos.2025.11.011","url":null,"abstract":"","PeriodicalId":36134,"journal":{"name":"Clinical Nutrition Open Science","volume":"65 ","pages":"Article 100604"},"PeriodicalIF":0.0,"publicationDate":"2025-12-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145842290","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}